S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$4.91
-1.8%
$5.67
$4.85
$12.43
$710.08M1.362.22 million shs1.15 million shs
Cambrex Co. stock logo
CBM
Cambrex
$59.99
$59.99
$33.80
$60.29
$2.02B2.14218,726 shsN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$329.83
$324.05
$158.38
$329.99
$12.58B1.18832,048 shs5 shs
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$68.03
0.0%
$70.58
$55.96
$75.31
$3.38B0.52237,137 shs171,413 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$26.77
-0.4%
$29.16
$25.76
$48.60
$1.24B0.76496,695 shs415,509 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
-0.79%-2.15%-3.29%-36.47%-53.53%
Cambrex Co. stock logo
CBM
Cambrex
0.00%0.00%0.00%0.00%0.00%
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00%0.00%0.00%+4.33%+66.88%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
-0.12%-1.60%-8.85%+15.69%+9.18%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
+1.28%-5.79%-8.64%-15.08%-37.90%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
0.9186 of 5 stars
3.41.00.00.02.30.00.6
Cambrex Co. stock logo
CBM
Cambrex
N/AN/AN/AN/AN/AN/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.0491 of 5 stars
1.20.00.00.00.01.70.6
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
4.0774 of 5 stars
3.34.00.03.52.52.50.6
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
4.9477 of 5 stars
4.53.00.03.92.52.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
2.75
Moderate Buy$10.00103.67% Upside
Cambrex Co. stock logo
CBM
Cambrex
N/AN/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
2.38
Hold$293.92-10.89% Downside
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
2.50
Moderate Buy$110.0061.69% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
3.00
Buy$49.5084.91% Upside

Current Analyst Ratings

Latest PBH, AUPH, KRTX, PCRX, and CBM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2024
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00
3/14/2024
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$330.00
3/7/2024
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$80.00 ➝ $45.00
3/4/2024
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$57.00
3/1/2024
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
3/1/2024
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$53.00 ➝ $45.00
3/1/2024
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00
2/23/2024
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$12.00 ➝ $10.00
2/22/2024
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $13.00
2/20/2024
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$330.00
2/16/2024
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold$9.50 ➝ $9.00
(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$175.51M4.05N/AN/A$2.63 per share1.87
Cambrex Co. stock logo
CBM
Cambrex
$532.09M3.80$3.91 per share15.36$19.48 per share3.08
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$654K19,239.07N/AN/A$33.24 per share9.92
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.13B3.00$5.00 per share13.60$29.12 per share2.34
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$674.98M1.84$4.00 per share6.70$18.74 per share1.43

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
-$78.02M-$0.54N/A8.93N/A-44.45%-20.10%-14.84%5/2/2024 (Confirmed)
Cambrex Co. stock logo
CBM
Cambrex
$92.41M$2.7721.66N/A5.96%5.38%2.50%N/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%5/2/2024 (Estimated)
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
-$82.31M-$1.64N/A14.761.85-7.11%14.09%6.39%5/2/2024 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$41.96M$0.8133.059.46N/A6.22%12.81%6.80%5/1/2024 (Estimated)

Latest PBH, AUPH, KRTX, PCRX, and CBM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
-$0.17N/A+$0.17N/AN/AN/A  
2/29/2024Q4 2023
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.71$0.71N/A$0.92$180.60 million$181.24 million
2/22/2024Q4 2023
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
-$2.65-$3.01-$0.36-$3.01$0.86 millionN/A
2/15/202412/31/2023
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
-$0.16-$0.19-$0.03-$0.19$45.00 million$45.10 million      
2/8/202412/31/2023
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.04$1.06+$0.02$1.06$280.25 million$282.74 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Cambrex Co. stock logo
CBM
Cambrex
N/AN/AN/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
0.20
5.50
4.99
Cambrex Co. stock logo
CBM
Cambrex
0.76
2.37
1.70
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
19.31
19.31
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
0.75
3.09
1.92
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.59
5.24
4.17

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
300144.62 million138.40 millionOptionable
Cambrex Co. stock logo
CBM
Cambrex
1,73233.72 millionN/AOptionable
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
33938.15 million33.16 millionOptionable
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
56049.65 million48.86 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
71246.50 million43.43 millionOptionable

PBH, AUPH, KRTX, PCRX, and CBM Headlines

SourceHeadline
Oversold Conditions For Pacira BioSciences (PCRX)Oversold Conditions For Pacira BioSciences (PCRX)
nasdaq.com - April 17 at 8:04 AM
Pacira BioSciences (NASDAQ:PCRX) Shares Up 2.7%Pacira BioSciences (NASDAQ:PCRX) Shares Up 2.7%
marketbeat.com - April 16 at 2:02 PM
Pacira BioSciences (NASDAQ:PCRX) Sets New 52-Week Low at $25.89Pacira BioSciences (NASDAQ:PCRX) Sets New 52-Week Low at $25.89
marketbeat.com - April 15 at 2:48 PM
Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trendPacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trend
finance.yahoo.com - April 11 at 9:46 AM
Baillie Gifford & Co. Sells 573,810 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Baillie Gifford & Co. Sells 573,810 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)
marketbeat.com - April 11 at 7:23 AM
Pacira BioSciences (NASDAQ:PCRX) Given Buy Rating at Needham & Company LLCPacira BioSciences (NASDAQ:PCRX) Given Buy Rating at Needham & Company LLC
americanbankingnews.com - April 10 at 4:16 AM
Understanding Key Factors Behind Pacira Pharmaceuticals’ Analyst RatingUnderstanding Key Factors Behind Pacira Pharmaceuticals’ Analyst Rating
markets.businessinsider.com - April 9 at 2:43 PM
Pacira BioSciences (NASDAQ:PCRX) Given "Buy" Rating at Needham & Company LLCPacira BioSciences (NASDAQ:PCRX) Given "Buy" Rating at Needham & Company LLC
marketbeat.com - April 9 at 8:30 AM
Commit To Purchase Pacira BioSciences At $15, Earn 12.5% Annualized Using OptionsCommit To Purchase Pacira BioSciences At $15, Earn 12.5% Annualized Using Options
nasdaq.com - April 6 at 9:01 AM
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferencePacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
globenewswire.com - April 2 at 8:00 AM
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Assenagon Asset Management S.A.Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Assenagon Asset Management S.A.
marketbeat.com - March 30 at 4:51 AM
Gradient Investments LLC Increases Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Gradient Investments LLC Increases Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)
marketbeat.com - March 29 at 3:45 PM
Tributary Capital Management LLC Raises Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Tributary Capital Management LLC Raises Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)
marketbeat.com - March 26 at 9:48 AM
Wellington Management Group LLP Lowers Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)Wellington Management Group LLP Lowers Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)
marketbeat.com - March 25 at 4:09 AM
Deutsche Bank AG Has $5.60 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Deutsche Bank AG Has $5.60 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)
marketbeat.com - March 22 at 4:16 AM
Gary W. Pace Sells 1,066 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) StockGary W. Pace Sells 1,066 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock
insidertrades.com - March 18 at 6:46 AM
PCRX Apr 2024 22.500 putPCRX Apr 2024 22.500 put
finance.yahoo.com - March 16 at 8:44 AM
Paciras (PCRX) Knee Osteoarthritis Drug Gets FDAs RMAT TagPacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
zacks.com - March 14 at 9:26 AM
Paciras PCRX-201 Gets FDA RMAT Designation in Knee OsteoarthritisPacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis
marketwatch.com - March 13 at 8:55 PM
Pacira BioSciences Receives RMAT Designation For Gene Therapy Product Candidate In OsteoarthritisPacira BioSciences Receives RMAT Designation For Gene Therapy Product Candidate In Osteoarthritis
markets.businessinsider.com - March 13 at 10:37 AM
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the KneePacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
globenewswire.com - March 13 at 7:00 AM
Pacira BioSciences, Inc. (NASDAQ:PCRX) Director Sells $2,754,000.00 in StockPacira BioSciences, Inc. (NASDAQ:PCRX) Director Sells $2,754,000.00 in Stock
insidertrades.com - March 11 at 5:35 AM
Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX)Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX)
finance.yahoo.com - March 9 at 7:05 AM
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare ConferencePacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
globenewswire.com - March 6 at 8:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aurinia Pharmaceuticals logo

Aurinia Pharmaceuticals

NASDAQ:AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Cambrex logo

Cambrex

NYSE:CBM
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
Karuna Therapeutics logo

Karuna Therapeutics

NASDAQ:KRTX
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Prestige Consumer Healthcare logo

Prestige Consumer Healthcare

NYSE:PBH
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Pacira BioSciences logo

Pacira BioSciences

NASDAQ:PCRX
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.